Impact of Optimized Ku–DNA Binding Inhibitors on the Cellular and In Vivo DNA Damage Response
Authors:
- Pamela L. Mendoza-MunozPMPamela L. Mendoza-Munoz
- Narva Deshwar KushwahaNarva Deshwar Kushwaha
- Dineshsinha ChauhanDCDineshsinha Chauhan
- Karim Ben Ali GacemKGKarim Ben Ali Gacem
- Joy E. GarrettJGJoy E. Garrett
- Joseph R. DynlachtJDJoseph R. Dynlacht
- Jean-Baptiste CharbonnierJCJean-Baptiste Charbonnier
- Navnath S. GavandeNavnath S. Gavande
- John J. TurchiJohn J. Turchi
Open Access
Abstract
Background: DNA-dependent protein kinase (DNA-PK) is a validated cancer therapeutic target involved in DNA damage response (DDR) and non-homologous end-joining (NHEJ) repair of DNA double-strand breaks (DSBs). Ku serves as a sensor of DSBs by binding to DNA ends and activating DNA-PK. Inhibition of DNA-PK is a common strategy to block DSB repair and improve efficacy of ionizing radiation (IR) therapy and radiomimetic drug therapies. We have previously developed Ku–DNA binding inhibitors (Ku-DBis) that block in vitro and cellular NHEJ activity, abrogate DNA-PK autophosphorylation, and potentiate cellular sensitivity to IR. Results and Conclusions: Here we report the discovery of oxindole Ku-DBis with improved cellular uptake and retained potent Ku-inhibitory activity. Variable monotherapy activity was observed in a panel of non-small cell lung cancer (NSCLC) cell lines, with ATM-null cells being the most sensitive and showing synergy with IR. BRCA1-deficient cells were resistant to single-agent treatment and antagonistic when combined with DSB-generating therapies. In vivo studies in an NSCLC xenograft model demonstrated that the Ku-DBi treatment blocked IR-dependent DNA-PKcs autophosphorylation, modulated DDR, and reduced tumor cell proliferation. This represents the first in vivo demonstration of a Ku-targeted DNA-binding inhibitor impacting IR response and highlights the potential therapeutic utility of Ku-DBis for cancer treatment.Keywords
Funding Information
- National Institutes of Health (R01 CA247370, ANR-20-CE11-0026, ANR 23-CE11-0033, ANR-23-CE18, CA247370)
- Tom and Julie Wood Family Foundation (R01 CA247370, ANR-20-CE11-0026, ANR 23-CE11-0033, ANR-23-CE18, CA247370)
- Agence Nationale de la Recherche France (R01 CA247370, ANR-20-CE11-0026, ANR 23-CE11-0033, ANR-23-CE18, CA247370)
- Sanofi (R01 CA247370, ANR-20-CE11-0026, ANR 23-CE11-0033, ANR-23-CE18, CA247370)
This publication has 35 references indexed in Scilit:
- BRCA2 promotes genomic integrity and therapy resistance primarily through its role in homology-directed repairMolecular Cell, 2024
- A Phase 1 Study of the DNA-PK Inhibitor Peposertib in Combination With Radiation Therapy With or Without Cisplatin in Patients With Advanced Head and Neck TumorsInternational Journal of Radiation Oncology - Biology - Physics (IJROBP), 2023
- Exploiting replication gaps for cancer therapyMolecular Cell, 2022
- Cryo-EM of NHEJ supercomplexes provides insights into DNA repairMolecular Cell, 2021
- Replication gaps are a key determinant of PARP inhibitor synthetic lethality with BRCA deficiencyMolecular Cell, 2021
- ATM, ATR, and DNA-PK: The Trinity at the Heart of the DNA Damage ResponseMolecular Cell, 2017
- Drugging the undruggable: Transcription therapy for cancerBiochimica et Biophysica Acta (BBA) - Reviews on Cancer, 2013
- Synthesis, DNA-PK inhibition, anti-platelet activity studies of 2-(N-substituted-3-aminopyridine)-substituted-1,3-benzoxazines and DNA-PK and PI3K inhibition, homology modelling studies of 2-morpholino-(7,8-di and 8-substituted)-1,3-benzoxazinesEuropean Journal of Medicinal Chemistry, 2012
- The role of homologous recombination in radiation-induced double-strand break repairRadiotherapy and Oncology, 2011
- Preparation of Nuclear and Cytoplasmic Extracts from Mammalian CellsCurrent Protocols in Molecular Biology, 2006